Institute of Nuclear Engineering and Science National Tsing Hua University Institute of Nuclear Engineering and Science National Tsing Hua University BNCT.

Slides:



Advertisements
Similar presentations
1 Neutron Source For Neutron Capture Therapy Of Cancer Tissues At Kyiv Research Reactor STCU Workshop "From Science to Business" 11 – 12 October 2006,
Advertisements

Lesson 16 Nuclear Medicine. What is Nuclear Medicine? Diagnosis and Treatment of Disease using small amounts of radio-nuclides (radiopharmaceuticals)
RapidArc plan verification using ArcCHECK™
Radiopharmaceutical Production Target Foil Characteristics STOP.
The Tomotherapy Experience at Advocate Good Samaritan Hospital
Esteban Fabián Boggio 1 Lucas Provenzano 2 Sara Gonzalez 2,3 Sara Gonzalez 2,3 Juan Manuel Longhino 1 1 Bariloche Atomic Center, Atomic Energy National.
Energy deposition and neutron background studies for a low energy proton therapy facility Roxana Rata*, Roger Barlow* * International Institute for Accelerator.
DEOEC Institute of Oncology Department of Radiotherapy.
Photon Beam Monitor-Unit Calculations
K. Oishi, K. Kosako and T. Nakamura Institute of Technology, Shimizu Corporation, Japan id=17 SATIF-10.
Para-spinal Tumors Encircling the Spinal Cord IMRT Comparison of Several Target Definitions.
E. Bavarnegin,Yaser Kasesaz, H. Khalafi
Radiation Protection in Radiotherapy
Clinical application of TCP ・ NTCP. Lyman JT. Complication probability as assessed from dosevolume histograms. Radiat Res Suppl 1985; 8:S13–S19. Because.
Radioisotopes in Medicine
بسم الله الرحمن الرحيم و قل رب زدنى علماً ﴿و قل رب زدنى علماً﴾ صدق الله العظيم.
Dr. Rico Liu Consultant, Department of Clinical Oncology, Queen Mary Hospital Honorary Clinical Associate Professor, Department of Clinical Oncology, The.
A novel therapy for liver metastases: a concrete hope after the first human treatment T.Pinelli*, A.Zonta +, S. Altieri*, S.Barni ++, A.Braghieri*, P.Pedroni*,
The Role of BPA-PET in Prediction of H&N Cancer Treatment failure after BNCT Yu-Ming Liu, Yi-Wei Chen, Pin-Lun Li, Ko-Han Lin, Yu-Wen Hu, Ling-Wei Wang.
Data Mining to Aid Beam Angle Selection for IMRT Stuart Price-University of Maryland Bruce Golden- University of Maryland Edward Wasil- American University.
A Study of Effective Dose for Tumor in BNCT Y. Sakurai, H. Tanaka, N. Fujimoto, N. Kondo, M. Narabayashi, Y. Nakagawa, T. Watanabe, Y. Kinashi, M. Suzuki,
H. Koivunoro1, E. Hippelänen1, I. Auterinen2, L. Kankaanranta3, M
Determination of gamma dose component in thermal column of Pavia Triga reactor by using alanine ESR detectors Saverio Altieri Department of Physics University.
ICNCT-16, , Helsinki, Finland
CTOS Soft Tissue Sarcoma of the Extremity Comparison of Conformal Post-operative Radiotherapy (CRT) and Intensity Modulated Radiotherapy (IMRT)
G. Bartesaghi, 11° ICATPP, Como, 5-9 October 2009 MONTE CARLO SIMULATIONS ON NEUTRON TRANSPORT AND ABSORBED DOSE IN TISSUE-EQUIVALENT PHANTOMS EXPOSED.
16 th International Congress on Neutron Capture Therapy June 14-19, Helsinki, Finland Improvement of a PGNAA Facility for BNCT in THOR C. K. Huang 1, H.
Clinical results of BNCT for Head and Neck melanoma J. Hiratsuka, N.Kamitani, N.Morita T.Aihara, A.Maruhashi * and K.Ono * Kawasaki Medical School *Research.
T. Aihara 1, 2, N. Morita 2, N. Kamitani 3, H. Kumada 1, K. Oonishi 1, M. Suzuki 4, J. Hiratsuka 3, H. Sakurai 1. 1 Proton Medical Research Centre, University.
Using Radiation in Medicine. There are 3 main uses of radiation in medicine: Treatment Diagnosis Sterilization.
Ye, Sung-Joon, Ph.D. Ove, Roger, M.D., Ph.D.; Shen, Sui, Ph.D.
Image-Guided Adaptive Therapy for the Treatment of Lung Cancer
Clinical decisions in the optimization process I. Emphasis on tumor control issues Avi Eisbruch University of Michigan.
Additive effect of BPA and Gd-DTPA for application in accelerator-based neutron source F. Yoshida, K. Nakai, T. Yamamoto, A. Zaboronok, A. Matsumura Department.
Design and construction of BNCT irradiation
N. Gubanova 1, V. Kanygin 2, A. Kichigin 3, S. Taskaev 4 1 Institute of Cytology and Genetics, Novosibirsk, Russia 2 Novosibirsk State Medical University,
1 Neutronics Assessment of Self-Cooled Li Blanket Concept Mohamed Sawan Fusion Technology Institute University of Wisconsin, Madison, WI With contributions.
Deterministic Parsing model of CBE factor for Intra-cellular 10 B Distribution in Boron Neutron Capture Therapy Shintaro ISHIYAMA ※ a and Yoshio IMAHORI.
The improvement of the energy resolution in epi-thermal region of Bonner sphere using boric acid solution moderator H. Ueda1, H. Tanaka2, Y. Sakurai2.
M Asnal *, T Liamsuwan 2 and T Onjun 1 1 Sirindhorn International Institute of Technology, Thammasat University 2 Nuclear Research and Development Division,
Introduction to Radiation Therapy
Optimization of Volumetric Modulated Arc Therapy (VMAT) Planning Strategy Using Ring-shaped ROI for Localized Prostate cancer Kentaro Ishii, Masako Hosono,
TLD POSTAL DOSE QUALITY AUDIT FOR 6MV AND 15MV PHOTON BEAMS IN RADIOTHERAPY CLINICAL PRACTICE Sonja Petkovska 1, Margarita Ginovska 2, Hristina Spasevska.
Photoneutron Distributions around 18 MV X-ray Radiotherapy Accelerators using Nuclear Track Detectors Fazal-ur-Rehman, H. Al-Ghamdi, M. I. Al-Jarallah.
A Proton Therapy Overview Richard Eckart And David Turberville Richard Eckart And David Turberville.
Overview of the BNCT neutron beam line facility in NRI Rez (Prague) Most pictures taken from presentation of J.Burian/NRI – Milano09 1 NRI = Nuclear research.
Saad El Din I, M.D *, Abd El AAl H, M.D *, Makaar W, M.D *, El Beih D, M.Sc †, Hashem W, M.Sc * *Department of Clinical Oncology and Radiotherapy, Kasr.
Purpose N-isopropylacrylamide (NIPAM) polymer gel dosimeters were employed to verify the dose distribution of clinical intensity modulated radiation therapy.
BNCT, a binary radiotherapy at cellular level
MCS overview in radiation therapy
Chapter 12 Therapeutic Heating Applications of Radio Frequency Energy C-K. Chou.
Hypothermia for Preventing Chemotherapy-Induced Peripheral Neuropathy
Principles of Radiation Oncology in (advanced stage) NSCLC
Electron Beam Therapy.
Radiological Sciences Department Ph.D., Paris-Sud 11 University
Feasibility of hippocampal sparing radiation therapy for glioblastoma using helical Tomotherapy Dr Kamalram THIPPU JAYAPRAKASH1,2,3, Dr Raj JENA1,4 and.
Introduction Materials & Methods Results Conclusion
USA Proton Therapy Market Renub Research
Fig. 4. Percentage of passing rate between clinical and 544 plans.
Reducing Treatment Time and MUs by using Dynamic Conformal Arc Therapy for SBRT Breath-Hold Patients Timothy Miller, Sebastian Nunez Albermann, Besil Raju,
Insert tables Insert figure
Median Volume (cc) of GTV Receiving Dose
Volumetric Modulated Arc Therapy (VMAT) versus Intensity Modulated Radiation Therapy (IMRT) for Anal Carcinoma Heather Ortega, BSRT(T), CMD, Kerry Hibbitts,
Dosimetry of Alternative Techniques for Accelerated Partial Breast Irradiation Hanh Pham, B.S, CMD, Thanh Nguyen, BS, Christina Henson, MD, Salahuddin.
Radioisotopes in Medicine
Ch 10. A System of Dosimetric Calculations
A Multi-Institutional Dosimetric Evaluation of Proton Versus Photon Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma F. Khan, B. Nguyen,
Sheng Yang a, Yen-Wan Hsueh Liu b
Hot and cold spots are common problems associated with planning:
Presentation transcript:

Institute of Nuclear Engineering and Science National Tsing Hua University Institute of Nuclear Engineering and Science National Tsing Hua University BNCT Treatment Planning for Superficial and Deep-Seated Tumors : Experience from Clinical Trial of Recurrent Head and Neck Cancer at THOR C.T. Chang a, L.Y. Yeh a, Y-W H. liu a, L.W. Wang b a Institute of Nuclear Engineering and Science, National Tsing Hua University, Hsinchu, Taiwan, ROC b Department of Oncology Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ROC June, 2014

Institute of Nuclear Engineering and Science National Tsing Hua University Outline Purpose Material & Method - Calculation tools - Calculation assumptions Case discussion - Treatment plannings for different tumor locations ◎ Patient 17 & Patient 16 Conclusion 2

Institute of Nuclear Engineering and Science National Tsing Hua University Purpose Oral cancer is the fifth of the top ten cancers announced in 2013 by Department of Health in Taiwan Currently, there is no effective treatment for recurrence head-and-neck cancer Under the collaboration between National Tsing Hua University and Taipei Veterans General Hospital, clinical trial of recurrent head-and-neck cancer using BNCT at Tsing Hua open-pool reactor(THOR) started on August 11, 2010 Up to January of 2014, 17 patients were treated This study shows the selection of treatment setup based on experience on patients with superficial and deep-seated tumors 3

Institute of Nuclear Engineering and Science National Tsing Hua University Material & Method Calculation tools Treatment Planning System THORplan MCNP 5 Boron drug : BPA Treatment planning assumptions Reactor power = 1.2MW Boron-10 in blood = 25ppm Target tumor dose : GTV D80 = 20Gy(W) RBE = 3.2 for neutron = 1 for gamma ray 4 CBE = 3.8 for tumor = 4.9 for mucosa = 2.5 for skin = 1.3 for other normal tissues

Institute of Nuclear Engineering and Science National Tsing Hua University Patient 17 (1st irradiation) Tumor volume : 73 cc The patient is in sitting position during irradiation Irradiated at 45 degrees (right and front) Tumor location (measured from the direction of irradiation) - tumor center to skin = 2.5 cm - deepest distance to skin = 5.5 cm Treatment Planning for Superficial tumor 45 〫 5

Institute of Nuclear Engineering and Science National Tsing Hua University Treatment Planning for Superficial tumor 6 Two conditions (1) Using patient collimator cm (2) No collimator (direct irradiation) Source-to-tumor center distance = 20.5 cm

Institute of Nuclear Engineering and Science National Tsing Hua University Flux(cm -2 -s -1 ) Flux comparison for superficial tumor treatment 7 Flux(cm -2 -s -1 ) axis (cm) Using collimator causes fluxes to be higher inside the patient collimator, up to 4.5 cm depth

Institute of Nuclear Engineering and Science National Tsing Hua University Patient 17-1 Direct IrradiationPatient Collimator Flux (cm -2 s -1 ) ThermalEpi.FastPhotonThermalEpi.FastPhoton GTV- D E+84.15E+82.12E+74.88E+73.95E+81.20E+85.13E+67.42E+7 At maximum dose point GTV (3.92) 8.04E+83.35E+81.22E+79.20E+79.26E+84.93E+81.74E+71.12E+8 Mucosa6.78E+81.75E+86.40E+68.20E+76.87E+82.31E+88.52E+69.33E+7 Brain3.74E+85.55E+72.18E+65.56E+72.01E+81.70E+71.17E+64.47E+7 Rt eyeball 4.52E+81.69E+85.36E+65.31E+72.34E+83.93E+71.69E+64.23E+7 Using collimator : gives higher thermal n fluxes for tissues inside the irradiation field ( +18% for GTV); gives lower thermal n fluxes for tissues outside the irradiation field (-46%, eyeball & brain). Thermal n flux at mucosa remains about the same Flux Comparison for Superficial tumor treatment 8 (↑ 18%) (↑ 15%) (↑ 1%) (↓ 46%) (↓ 48%)

Institute of Nuclear Engineering and Science National Tsing Hua University Dose Rate Comparison for Superficial Tumor Treatment Using collimator results in higher dose rate (+16%) at GTV-D80 (& GTV max), therefore shorter irradiation time The increase of max dose rate at mucosa is only 2%; for brain and Rt eyeball, the max dose rate decrease by ~40%. Therefore, the maximum dose of mucosa, brain and Rt eyeball decrease. For superficial tumor, using patient collimator helps to protect the normal tissues especially those outside the irradiation field Patient 17-1 Direct Irradiation (Irradiation time = min) Patient Collimator (Irradiation time = min) Dose Gy(W) Dose Rate (Gy(W) s -1 ) Dose Gy(W) Dose Rate (Gy(W) s -1 ) PhotonB10H1N14TotalPhotonB10H1N14Total GTV- D E-49.08E-34.62E-42.43E-41.01E E-41.07E-22.12E-42.85E-41.17E-2 At maximum dose location GTV (3.92) E-42.18E-23.77E-45.79E-42.33E E-42.50E-24.63E-46.66E-42.69E-2 Mucosa E-46.10E-32.41E-46.10E-47.52E E-46.13E-32.92E-46.13E-47.70E-3 Brain E-48.95E-41.01E-41.77E-41.54E E-44.85E-46.11E-59.58E-59.33E-4 Rt eyeball E-41.07E-31.61E-45.50E-42.16E E-45.59E-47.53E-52.86E-41.22E-3 (↑ 16%) (↑ 15%) (↑ 2%) (↓ 39%) (↓ 44%) 9

Institute of Nuclear Engineering and Science National Tsing Hua University 10 Treatment Planning for Patient 17 Target: GTV D80 = 27 Gy(W) Boron concentration in blood =25ppm Reactor power =1.2 MW Irradiation time = 38.4 minutes Max. Dose Gy(W) Dose Limit Gy(W) Skin Mucosa Rt eyeball Mucosa over dose limit < 10.6 cc GTVMeanMax.Min. Gy(W) In order to limit the volume of mucosa over 10 Gy(W) less than 10 cc, GTV D80 was set to 27Gy(W) during treatment planning The boron concentration in blood was assumed to be 25ppm For reactor power of 1.2 MW, the estimated irradiation time was 38 minutes Except for mucosa, dose of normal tissues were expected to be within the dose limits Volume of mucosa over 10 Gy is < 10 cc

Institute of Nuclear Engineering and Science National Tsing Hua University 11 Final Treatment of Patient 17 GTV D80 = 26.5 Gy (W) Reactor power = 1.62 MW Boron concentration in blood = 30ppm Irradiation time = 23.4 minutes Max. Dose Gy(W) Skin9.09 Mucosa17.11 Rt eyeball2.53 Mucosa over dose limit < 9.5 cc GTVMeanMax.Min. Gy(W) The boron concentration of patient was measured to be 30 ppm. The treatment was done using reactor power =1.6 MW. The irradiation time is 23 Minutes. The GTV D80 is 26.5 Gy (W), very closed to the prescribed dose 27 Gy (W).

Institute of Nuclear Engineering and Science National Tsing Hua University 12 DVH for Patient 17

Institute of Nuclear Engineering and Science National Tsing Hua University Patient 16 (1st irradiation) Tumor volume : 8.2 cc Irradiated from left-hand side Tumor location (measured from the direction of irradiation) - tumor center to skin = 6.5 cm - deepest distance to skin = 7.7 cm Treatment Planning for Deep-seated tumor 13

Institute of Nuclear Engineering and Science National Tsing Hua University Consider three conditions -- I. Direct irradiation -- II. Patient collimator 10 (long)-10(exit diameter)-1.5 cm (thickness) -- III. Lithium pad 2.5cm thick natural Li 2 CO 3 (size 40*40 cm) + 0.5cm thick enriched Li 2 CO 3 (size 5*5 cm) Source to tumor center distance =19 cm Source to skin distance = 12.5 cm Treatment Planning for Deep-seated tumor 14

Institute of Nuclear Engineering and Science National Tsing Hua University 15 Flux comparison for Deep-seated tumor along the beam direction Axis (cm) Flux(cm -2 -s -1 ) For deep-seated tumors, the situation is different. When using collimator, the thermal neutron flux at GTV decrease.

Institute of Nuclear Engineering and Science National Tsing Hua University Patient 16-1 Condition I. Direct irradiationCondition II. Patient Collimator Flux (cm -2 s -1 ) ThermalEpi.FastPhotonThermalEpi.FastPhoton GTV-D804.39E+83.55E+73.01E+69.31E+74.04E+83.03E+72.95E+61.03E+8 At maximum dose point GTV (2.72)8.06E+81.13E+85.72E+61.25E+88.00E+81.14E+85.78E+61.37E+8 Skin1.09E+95.06E+82.02E+71.24E+81.11E+95.21E+82.05E+71.38E+8 Mucosa7.56E+81.58E+86.87E+61.05E+87.46E+81.56E+86.98E+61.17E+8 Brain1.21E+94.23E+81.55E+71.40E+81.26E+94.41E+81.58E+71.58E+8 Lt eyelens3.91E+82.56E+81.13E+76.20E+73.57E+81.98E+89.34E+67.10E+7 (↓ 8%) (↓ 1%) (↑ 2%) (↓ 1%) (↑ 4%) (↓ 9%) When using collimator, the thermal neutron flux at GTV-D80 decreases by 8%. Thermal neutron flux of most of the normal tissues change only 1~2% Flux Comparison for Deep-seated tumor 16

Institute of Nuclear Engineering and Science National Tsing Hua University When using collimator, the dose rate at GTV-D80 is lower by 6%, results in longer irrad. time Dose rates of normal tissues either increases or decreases only slightly. Therefore, max dose of most of the normal tissues increase. For deep-seated tumors, using collimator has no benefits Dose rate Comparison for Deep-seated tumor Patient 16-1 Condition I. Direct irradiation (Irradiation time = min) Condition II. Patient Collimator (Irradiation time = min) Dose Gy(W) Dose Rate (Gy(W) s -1 ) Dose Gy(W) Dose Rate (Gy(W) s -1 ) PhotonB10H1N14TotalPhotonB10H1N14Total GTV- D E-48.43E-31.56E-43.23E-49.52E E-47.77E-31.54E-42.98E-48.93E-3 At maximum dose point GTV (2.72) E-41.54E-22.61E-45.89E-41.71E E-41.52E-22.63E-45.84E-41.71E-2 Skin E-44.97E-35.28E-49.75E-47.37E E-35.09E-35.37E-49.98E-47.67E-3 Mucosa E-46.82E-32.79E-46.82E-48.51E E-46.72E-32.83E-46.71E-48.51E-3 Brain E-42.87E-35.07E-45.66E-44.94E E-32.99E-35.18E-45.90E-45.27E-3 Lt eyelens E-49.22E-42.99E-44.73E-42.13E E-48.39E-42.72E-44.30E-42.07E-3 (↓ 6%) (↑ 4%) (↑ 7%) (↓ 3%) 17

Institute of Nuclear Engineering and Science National Tsing Hua University Using Lithium Pad for Skin Protection 18 The maximum dose for normal tissues is still high for the direct irradiation condition Li 2 CO 3 is used to reduce the skin maximum dose 2.5cm thick natural Li 2 CO 3 (size 40*40 cm) + 0.5cm thick enriched Li 2 CO 3 (size 5*5 cm)

Institute of Nuclear Engineering and Science National Tsing Hua University Using lithium pad results in much lower fluxes for all tissues compared to direct irradiation Thermal neutron flux at GTV D80 decreases by 30% For skin and mucosa, thermal neutron fluxes decrease more than GTV D80 Patient 16-1 Condition I. Direct irradiation Condition III. Natural lithium pad + Enriched lithium Flux (cm -2 sec -1 ) ThermalEpi.FastPhotonThermalEpi.FastPhoton GTV- D E+83.55E+73.01E+69.31E E+82.67E+72.47E+67.91E+7 At maximum dose point GTV (2.72) 8.06E+81.13E+85.72E+61.25E E+88.04E+74.50E+61.02E+8 Skin 1.09E+95.06E+82.02E+71.24E E+83.59E+81.54E+71.00E+8 Mucosa 7.56E+81.58E+86.87E+61.05E E+81.15E+85.35E+68.58E+7 Brain 1.22E+94.44E+81.63E+71.40E E+83.05E+81.18E+71.11E+8 Lt eyelens 3.91E+82.56E+81.13E+76.20E E+81.86E+88.58E+65.33E+7 (↓ 30%) (↓ 33%) (↓ 35%) (↓ 32%) (↓ 35%) Flux Comparison for Deep-seated tumor 19

Institute of Nuclear Engineering and Science National Tsing Hua University Dose rate Comparison for Deep-seated tumor Patient 16-1 Condition I. Direct irradiation (Irradiation time = min) Condition III. Natural lithium pad + Enriched lithium (Irradiation time = min) Dose Gy(W) Dose Rate (Gy(W) s -1 ) Dose Gy(W) Dose Rate (Gy(W) s -1 ) PhotonB10H1N14TotalPhotonB10H1N14Total GTV-D E-48.43E-31.56E-43.23E-49.52E E-45.86E-31.30E-42.25E-46.76E-3 At maximum point GTV (2.72) E-41.54E-22.61E-45.89E-41.71E E-41.04E-22.10E-43.98E-41.17E-2 Skin E-44.97E-35.28E-49.75E-47.37E E-43.22E-34.18E-46.32E-45.03E-3 Mucosa E-46.82E-32.79E-46.82E-48.51E E-44.64E-32.24E-44.65E-45.96E-3 Brain E-42.91E-35.22E-45.74E-45.00E E-41.89E-34.02E-43.73E-43.49E-3 Lt eye lens E-49.22E-42.99E-44.73E-42.13E E-46.07E-42.37E-43.12E-41.56E-3 (↓ 29%) (↓ 32%) (↓ 30%) (↓ 27%) The dose rate reduction at GTV-D80 is 29%, the irradiation time is longer. The dose rate reduction at skin is 32%, therefore the maximum dose of skin is lower. Using lithium pad has protection effect for normal tissues 20

Institute of Nuclear Engineering and Science National Tsing Hua University 21 Final Treatment of Patient 16 GTV D80 = 19 Gy(W) Reactor power = 1.8 MW Boron concentration in blood =21ppm Irradiation time = 35 minutes Max. Dose Gy(W) Skin14.75 Mucosa17.11 Lt eyelens4.81 Skin over dose limit < 2.8 cc Mucosa over dose limit < 24 cc GTVMeanMax.Min. Gy(W) Mucosa max.

Institute of Nuclear Engineering and Science National Tsing Hua University Conclusions The preferred patient setups are different for tumors at different depth For superficial tumors, using patient collimator is better than direct irradiation On the other hand, for deep-seated tumors, direct irradiation or attaching lithium pads at beam exit are better choices Tumor response of Patient 17 (superficial tumor) is PR, of Patient 16 (deep-seated tumor) is CR Minimum dose of GTV of patient 16 is 15.6 Gy (W), higher then patient 17 (12.6 Gy (W)). 22

Institute of Nuclear Engineering and Science National Tsing Hua University 23 References H.S. Li, Y-W H. Liu, C.Y. Lee, T.Y Lin, F.Y. Hsu, “Verification of the accuracy of BNCT treatment planning system THORplan”, Appl. Radiat. Isot. 67 (2009), S122–S125. T.Y Lin, Y-W H. Liu, “Development and verification of THORplan—A BNCT treatment planning system for THOR”, Appl. Radiat. Isot. 69 (2011) 1878– H.T. Yu, Y-W. H. Liu, T.Y. Lin, L.W. Wang, “BNCT treatment planning of recurrent head-and-neck cancer using THORplan”, Appl. Radiat. Isot. 69 (2011) 1907–1910. Ling-Wei Wang, Yi-Wei Chen, Ching-Yin Ho, Yen-Wan Hsueh Liu, Fong-In Chou, Yuan-Hao Liu, Hong-Ming Liu, Jinn-Jer Peir, Shiang-Huei Jiang, Chi- Wei Chang, Ching-Sheng Liu, Shyh-Jen Wang, Pen-Yuan Chu, Sang-Hue Yen, Fractionated BNCT for locally recurrent head and neck cancer: Experience from a phase I/II clinical trial at Tsing Hua Open-Pool Reactor, Appl. Radiat. Isot. (in press)

Institute of Nuclear Engineering and Science National Tsing Hua University 24 Thanks for your attention

Institute of Nuclear Engineering and Science National Tsing Hua University Patien t 16-1 Condition I. Direct irradiation Condition III. Natural lithium pad + Enriched lithium pad Max. Dose (Gy(W)) Dose Component (Gy(W)) Max. Dose (Gy(W)) Dose Component (Gy(W)) PhotonB10H1N14OtherPhotonB10H1N14Other Mucosa Brain Lt eyelens Mucosa max. The use of lithium pad helps to reduce the boron doses but the photon doses also increase For eyelens, though the maximum dose is higher when using lithium pad, it is still under the dose limitation (5Gy) The maximum dose of mucosa can not be easily reduced since it locates nearby the tumor Dose Component (at GTV D80=20 Gy(W)) 25

Institute of Nuclear Engineering and Science National Tsing Hua University 26 Mucosa dose Maximum point for Superficial Tumor Direct irradiationPatient collimator

Institute of Nuclear Engineering and Science National Tsing Hua University 27 Standard deviation Neutron < 1% Gamma < 2% Computer time (1 core) Patient 16 =3.5 hours Patient 17 = 17 hours

Institute of Nuclear Engineering and Science National Tsing Hua University 28 Boron dose %